<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565903</url>
  </required_header>
  <id_info>
    <org_study_id>05-0192 / 201012830</org_study_id>
    <nct_id>NCT00565903</nct_id>
  </id_info>
  <brief_title>Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome</brief_title>
  <acronym>PPB</acronym>
  <official_title>Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>D. Ashley Hill, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's National Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pleuropulmonary Blastoma (PPB) is a rare lung tumor which develops in childhood. The
      underlying genetic factors which contribute to the development and progression of PPB are not
      defined. We are working to identify the genetic factors which may contribute to the
      development of this rare tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies of inherited cancer syndromes have provided unique opportunities to uncover and
      explain important cellular pathways with broad relevance to both sporadic cancers and human
      development. This proposal studies the cancer predisposition syndrome originally described as
      a familial form of pleuropulmonary blastoma (PPB). PPB is a rare, aggressive lung cancer that
      affects young children. Children with PPB and/or their family members are at increased risk
      for a number of rare conditions, including Wilms tumor, rhabdomyosarcoma, brain tumors,
      ovarian tumors and nodular hyperplasia of the thyroid gland. In 2009, we mapped a PPB locus
      and identified germline, loss of function mutations in one copy of DICER1 as the genetic
      basis of this syndrome. DICER1 encodes a protein that performs the final critical step in
      maturation of microRNAs (miRNAs). miRNAs are an important form of gene regulation. The
      syndrome's varied nature is likely attributable to the various roles of miRNAs during
      different developmental and/or functional circumstances. This study focuses on defining the
      full phenotype of this cancer predisposition syndrome including penetrance, expressivity in
      children and adults, pathologic classification of disease and spectrum of predisposing DICER1
      mutations. Improved understanding of the clinical and genetic features of this cancer
      predisposition syndrome is essential to facilitate early diagnosis when the diseases are most
      curable, and to create genetic counseling and educational materials to guide medical care.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify the genetic factors which contribute to the development or progression of pleuropulmonary blastoma</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define the clinical features of the pleuropulmonary blastoma (PPB) familial cancer syndrome.</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Pleuropulmonary Blastoma</condition>
  <condition>Cystic Nephroma</condition>
  <condition>Sertoli-Leydig Cell Tumor of Ovary</condition>
  <condition>Medulloepithelioma</condition>
  <condition>Embryonal Rhabdomyosarcoma of Cervix</condition>
  <condition>Goiter</condition>
  <condition>Sarcoma</condition>
  <condition>Pineoblastoma</condition>
  <condition>Pituitary Tumors</condition>
  <condition>Wilms Tumor</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We are collecting blood samples or saliva samples. When available, we also collect tumor
      samples from prior surgical procedures.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Families who have a child or adult with pleuropulmonary blastoma or cystic nephroma are
        invited to participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child or adult diagnosed with pleuropulmonary blastoma, cystic nephroma, embryonal
             rhabdomyosarcoma of uterine cervix, ovarian Sertoli-Leydig tumor or gynandroblastoma,
             pineoblastoma, pituitary blastoma, nasal chondromesenchymal hamartoma,
             medulloepithelioma, Wilms tumor, germline or mosaic DICER1 mutation

        Exclusion Criteria:

          -  child or adult who does not fit inclusion criteria as listed above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Ashley Hill, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kris Ann Schultz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital and Clinics of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ppbgeneticstudy.org</url>
    <description>PPB Research Program website</description>
  </link>
  <results_reference>
    <citation>Schultz KAP, Williams GM, Kamihara J, Stewart DR, Harris AK, Bauer AJ, Turner J, Shah R, Schneider K, Schneider KW, Carr AG, Harney LA, Baldinger S, Frazier AL, Orbach D, Schneider DT, Malkin D, Dehner LP, Messinger YH, Hill DA. DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies. Clin Cancer Res. 2018 May 15;24(10):2251-2261. doi: 10.1158/1078-0432.CCR-17-3089. Epub 2018 Jan 17. Review.</citation>
    <PMID>29343557</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KAP, Harris AK, Finch M, Dehner LP, Brown JB, Gershenson DM, Young RH, Field A, Yu W, Turner J, Cost NG, Schneider DT, Stewart DR, Frazier AL, Messinger Y, Hill DA. DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. Gynecol Oncol. 2017 Dec;147(3):521-527. doi: 10.1016/j.ygyno.2017.09.034. Epub 2017 Oct 14.</citation>
    <PMID>29037807</PMID>
  </results_reference>
  <results_reference>
    <citation>Hill DA, Ivanovich J, Priest JR, Gurnett CA, Dehner LP, Desruisseau D, Jarzembowski JA, Wikenheiser-Brokamp KA, Suarez BK, Whelan AJ, Williams G, Bracamontes D, Messinger Y, Goodfellow PJ. DICER1 mutations in familial pleuropulmonary blastoma. Science. 2009 Aug 21;325(5943):965. doi: 10.1126/science.1174334. Epub 2009 Jun 25.</citation>
    <PMID>19556464</PMID>
  </results_reference>
  <results_reference>
    <citation>Pugh TJ, Yu W, Yang J, Field AL, Ambrogio L, Carter SL, Cibulskis K, Giannikopoulos P, Kiezun A, Kim J, McKenna A, Nickerson E, Getz G, Hoffher S, Messinger YH, Dehner LP, Roberts CW, Rodriguez-Galindo C, Williams GM, Rossi CT, Meyerson M, Hill DA. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene. 2014 Nov 6;33(45):5295-302. doi: 10.1038/onc.2014.150. Epub 2014 Jun 9.</citation>
    <PMID>24909177</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KA, Harris A, Williams GM, Baldinger S, Doros L, Valusek P, Frazier AL, Dehner LP, Messinger Y, Hill DA. Judicious DICER1 testing and surveillance imaging facilitates early diagnosis and cure of pleuropulmonary blastoma. Pediatr Blood Cancer. 2014 Sep;61(9):1695-7. doi: 10.1002/pbc.25092. Epub 2014 May 13.</citation>
    <PMID>24821309</PMID>
  </results_reference>
  <results_reference>
    <citation>Doros LA, Rossi CT, Yang J, Field A, Williams GM, Messinger Y, Cajaiba MM, Perlman EJ, A Schultz K, Cathro HP, Legallo RD, LaFortune KA, Chikwava KR, Faria P, Geller JI, Dome JS, Mullen EA, Gratias EJ, Dehner LP, Hill DA. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Mod Pathol. 2014 Sep;27(9):1267-80. doi: 10.1038/modpathol.2013.242. Epub 2014 Jan 31.</citation>
    <PMID>24481001</PMID>
  </results_reference>
  <results_reference>
    <citation>Stewart DR, Messinger Y, Williams GM, Yang J, Field A, Schultz KA, Harney LA, Doros LA, Dehner LP, Hill DA. Nasal chondromesenchymal hamartomas arise secondary to germline and somatic mutations of DICER1 in the pleuropulmonary blastoma tumor predisposition disorder. Hum Genet. 2014 Nov;133(11):1443-50. doi: 10.1007/s00439-014-1474-9. Epub 2014 Aug 14.</citation>
    <PMID>25118636</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KA, Yang J, Doros L, Williams GM, Harris A, Stewart DR, Messinger Y, Field A, Dehner LP, Hill DA. DICER1-pleuropulmonary blastoma familial tumor predisposition syndrome: a unique constellation of neoplastic conditions. Pathol Case Rev. 2014 Mar;19(2):90-100.</citation>
    <PMID>25356068</PMID>
  </results_reference>
  <results_reference>
    <citation>Messinger YH, Stewart DR, Priest JR, Williams GM, Harris AK, Schultz KA, Yang J, Doros L, Rosenberg PS, Hill DA, Dehner LP. Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry. Cancer. 2015 Jan 15;121(2):276-85. doi: 10.1002/cncr.29032. Epub 2014 Sep 10.</citation>
    <PMID>25209242</PMID>
  </results_reference>
  <results_reference>
    <citation>Rutter MM, Jha P, Schultz KA, Sheil A, Harris AK, Bauer AJ, Field AL, Geller J, Hill DA. DICER1 Mutations and Differentiated Thyroid Carcinoma: Evidence of a Direct Association. J Clin Endocrinol Metab. 2016 Jan;101(1):1-5. doi: 10.1210/jc.2015-2169. Epub 2015 Nov 10.</citation>
    <PMID>26555935</PMID>
  </results_reference>
  <results_reference>
    <citation>Khan NE, Bauer AJ, Schultz KAP, Doros L, Decastro RM, Ling A, Lodish MB, Harney LA, Kase RG, Carr AG, Rossi CT, Field A, Harris AK, Williams GM, Dehner LP, Messinger YH, Hill DA, Stewart DR. Quantification of Thyroid Cancer and Multinodular Goiter Risk in the DICER1 Syndrome: A Family-Based Cohort Study. J Clin Endocrinol Metab. 2017 May 1;102(5):1614-1622. doi: 10.1210/jc.2016-2954.</citation>
    <PMID>28323992</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim J, Field A, Schultz KAP, Hill DA, Stewart DR. The prevalence of DICER1 pathogenic variation in population databases. Int J Cancer. 2017 Nov 15;141(10):2030-2036. doi: 10.1002/ijc.30907. Epub 2017 Aug 21.</citation>
    <PMID>28748527</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KAP, Stewart DR, Kamihara J, Bauer AJ, Merideth MA, Stratton P, Huryn LA, Harris AK, Doros L, Field A, Carr AG, Dehner LP, Messinger Y, Hill DA. DICER1 Tumor Predisposition. 2014 Apr 24 [updated 2020 Apr 30]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK196157/</citation>
    <PMID>24761742</PMID>
  </results_reference>
  <results_reference>
    <citation>Brenneman M, Field A, Yang J, Williams G, Doros L, Rossi C, Schultz KA, Rosenberg A, Ivanovich J, Turner J, Gordish-Dressman H, Stewart D, Yu W, Harris A, Schoettler P, Goodfellow P, Dehner L, Messinger Y, Hill DA. Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma / DICER1 syndrome: a unique variant of the two-hit tumor suppression model. Version 2. F1000Res. 2015 Jul 10 [revised 2018 Jan 1];4:214. doi: 10.12688/f1000research.6746.2. eCollection 2015.</citation>
    <PMID>26925222</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's National Research Institute</investigator_affiliation>
    <investigator_full_name>D. Ashley Hill, M.D.</investigator_full_name>
    <investigator_title>MD, Division Chief Pathology</investigator_title>
  </responsible_party>
  <keyword>pleuropulmonary blastoma</keyword>
  <keyword>PPB</keyword>
  <keyword>cystic nephroma</keyword>
  <keyword>DICER1</keyword>
  <keyword>miRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
    <mesh_term>Pulmonary Blastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Rhabdomyosarcoma, Embryonal</mesh_term>
    <mesh_term>Leydig Cell Tumor</mesh_term>
    <mesh_term>Sertoli-Leydig Cell Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Sequence data deposited in ClinVar upon publication. Publication of all final results in NIHMS</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

